CoChat

Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders

Ipser, Jonathan C, Carey, Paul, Dhansay, Yumna, Fakier, Nuraan, Seedat, Soraya, Stein, Dan J · 2006 · Cochrane Database of Systematic Reviews
Cited by 93

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

BACKGROUND: A large proportion of patients with anxiety disorders fail to respond to first-line medication interventions, despite evidence of the effectiveness of these agents. OBJECTIVES: To assess the effects of medication versus placebo augmentation in the treatment of patients with anxiety disorders who have failed to respond adequately to first-line drug therapies. SEARCH STRATEGY: The Cochrane Depression, Anxiety & Neurosis Group (CCDAN) specialised registers (CCDANCTR-Studies and CCDANCTR-References) were searched on 3/8/2005, MEDLINE (January 1966 to July 2005) and PsycINFO (1966 to 2005, Part A). Unpublished trials were identified through the Controlled Trials database and the National Institute of Health's Computer Retrieval of Information on Scientific Projects (CRISP) service (1972 to 2005). Additional studies in any language were sought in reference lists of retrieved articles. SELECTION CRITERIA: All randomised controlled trials (RCTs) of the medication augmentation of pharmacotherapy for treatment resistant anxiety disorders. DATA COLLECTION AND ANALYSIS: Two raters independently assessed RCTs for inclusion in the review, collated trial data, and assessed trial quality. Investigators were contacted to obtain missing data. Summary statistics were stratified by class of augmentation agent and anxiety disorder. Overall effect estimates were calculated using a random-effects model, heterogeneity was assessed and subgroup/sensitivity analyses were undertaken. MAIN RESULTS: Twenty eight short-term (average of seven weeks) randomised controlled trials (740 participants) were included in the review, 20 of which investigated augmentation of medication for treatment-resistant obsessive compulsive disorder (OCD). Summary statistics for responder status from nine trials demonstrate overall superiority of a variety of medication agents to placebo (relative risk of non-response (RR) 3.16, 95% CI 1.08 to 9.23). Similarly, symptom severity was significantly reduced in the medication groups, relative to placebo (number of trials (N) = 14, standardised mean difference (SMD) -0.87, 95% CI -1.37 to -0.36). There is no evidence of a difference between medication and placebo in total dropout rate, or in the number of dropouts due to adverse events. AUTHORS' CONCLUSIONS: Medication augmentation can be an effective and well-tolerated short-term treatment strategy for non-responders to first-line pharmacotherapy of anxiety disorders. However, any conclusions must be tentative in view of methodological and clinical heterogeneity, and the fact that much of the relevant database is based on antipsychotic augmentation trials in OCD patients resistant to serotonin reuptake inhibitors (SRIs). Additional data are needed to address several areas, including the efficacy of augmentation over the longer-term, and the value of medication augmentation in comparison to other strategies (e.g. switching medication, adding psychotherapy).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd005473.pub2

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 82

  1. Atmaca, 2002, Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study, International Clinical Psychopharmacology, 17, 115, 10.1097/00004850-200205000-00004 · DOI · Paper page
  2. Barr, 1997, Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder, American Journal of Psychiatry, 154, 1293, 10.1176/ajp.154.9.1293 · DOI · Paper page
  3. Bartzokis, 2004, Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder, Biological Psychiatry, 57, 474, 10.1016/j.biopsych.2004.11.039 · DOI · Paper page
  4. Brawman-Mintzer O Knapp R Nietert P Placebo-controlled study of risperidone augmentation in treatment-resistant subjects with DSM-IV diagnosed generalized anxiety disorder conference poster
  5. Dannon, 2000, Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial, European Neuropsychopharmacology, 10, 165, 10.1016/S0924-977X(00)00065-1 · DOI
  6. Erzegovesi, 2005, Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study, European Neuropsychopharmacology, 15, 69, 10.1016/j.euroneuro.2004.04.004 · DOI
  7. Fux, 1999, Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study, International Journal of Neuropsychopharmacology, 2, 193, 10.1017/S1461145799001546 · DOI · Paper page
  8. Hamner, 2003, Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms, International Clinical Psychopharmacology, 18, 1, 10.1097/00004850-200301000-00001 · DOI · Paper page
  9. Koran, 2005, Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder, Journal of Clinical Psychiatry, 66, 353, 10.4088/JCP.v66n0312 · DOI · Paper page
  10. McDougle, 1991, A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy, Journal of Clinical Psychopharmacology, 11, 175, 10.1097/00004714-199106000-00005 · DOI · Paper page
  11. McDougle, 1991, A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy, Journal of Clinical Psychopharmacology, 11, 175, 10.1097/00004714-199106000-00005 · DOI · Paper page
  12. McDougle, 1993, Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder, American Journal of Psychiatry, 150, 647, 10.1176/ajp.150.4.647 · DOI · Paper page
  13. McDougle, 1994, Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics, Archives of General Psychiatry, 51, 302, 10.1001/archpsyc.1994.03950040046006 · DOI · Paper page
  14. Pallanti, 1999, Citalopram for treatment-resistant obsessive-compulsive disorder, European Psychiatry, 14, 101, 10.1016/S0924-9338(99)80725-1 · DOI · Paper page
  15. Pigott, 1991, A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder, Journal of Clinical Psychopharmacology, 11, 242, 10.1097/00004714-199108000-00004 · DOI · Paper page
  16. Pollack, 2006, Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: A placebo controlled study, Biological Psychiatry, 59, 211, 10.1016/j.biopsych.2005.07.005 · DOI
  17. Raskind, 2003, Reducation of nightmares and other PTSD symptoms in combat veterans by prazosin: A placebo-controlled study, American Journal of Psychiatry, 160, 371, 10.1176/appi.ajp.160.2.371 · DOI · Paper page
  18. Shapira, 2004, A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder, Biological Psychiatry, 55, 553, 10.1016/j.biopsych.2003.11.010 · DOI
  19. Stein, 2001, Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study, American Journal of Psychiatry, 158, 1725, 10.1176/appi.ajp.158.10.1725 · DOI · Paper page
  20. Stein, 2002, Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study, American Journal of Psychiatry, 159, 1777, 10.1176/appi.ajp.159.10.1777 · DOI · Paper page
  21. Denys, 2004, A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder, Journal of Clinical Psychiatry, 65, 37, 10.4088/JCP.v65n0106 · DOI · Paper page
  22. Fallon, 1998, Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine, Archives of General Psychiatry, 55, 918, 10.1001/archpsyc.55.10.918 · DOI · Paper page
  23. Grady, 1993, Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder, American Journal of Psychiatry, 150, 819, 10.1176/ajp.150.5.819 · DOI · Paper page
  24. Mundo, 1998, Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study, International Clinical Psychopharmacology, 13, 219, 10.1097/00004850-199809000-00005 · DOI · Paper page
  25. Pallanti, 2004, Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: A pilot study, Journal of Clinical Psychiatry, 65, 1394, 10.4088/JCP.v65n1015 · DOI · Paper page
  26. Pigott, 1992, A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder, Journal of Clinical Psychopharmacology, 12, 11, 10.1097/00004714-199202000-00003 · DOI · Paper page
  27. Pollack, 2003, Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder, Journal of Psychopharmacology, 17, 276, 10.1177/02698811030173009 · DOI · Paper page
  28. Fux, 2004, A placebo-controlled cross-over trial of adjunctive EPA in OCD, Journal of Psychiatric Research, 38, 323, 10.1016/S0022-3956(03)00077-3 · DOI
  29. Ackerman, 2002, Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder, Journal of Clinical Psychopharmacology, 22, 309, 10.1097/00004714-200206000-00012 · DOI · Paper page
  30. Alderson, 2004, Assessment of study quality
  31. American Psychiatric Association, 1994, Diagnostic and statistical manual of mental disorders
  32. Arias F Soto JA Garcia MJ Rodriguez-Calvin JL Morales J Salgado M Efficacy and tolerance of risperidone addition in serotonin reuptake inhibitors (SRI) treatment for refractory obsessive compulsive disorder [Abstract] Journal of the European College of Neuropsychopharmacology 2002 S341 · doi:10.1016/s0924-977x(02)80534-x
  33. Baker, 2003, Quantitative analysis of sponsorship bias in economic studies of antidepressants, British Journal of Psychiatry, 183, 498, 10.1192/bjp.183.6.498 · doi:10.1192/bjp.183.6.498 · Paper page
  34. Bakker, 2002, SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis, Acta Psychiatrica Scandinavica, 106, 163, 10.1034/j.1600-0447.2002.02255.x · DOI · Paper page
  35. Bandelow, 2002, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders, World Journal of Biological Psychiatry, 3, 171, 10.3109/15622970209150621 · DOI · Paper page
  36. Baldwin, 2005, Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology, Journal of Psychopharmacology, 19, 567, 10.1177/0269881105059253 · DOI · Paper page
  37. Berlin, 1999, Measuring the quality of trials: The quality of quality scales, JAMA, 282, 1083, 10.1001/jama.282.11.1083 · DOI
  38. Blanco, 2003, Pharmalogical treatment of social anxiety disorder: A meta-analysis, Depression and Anxiety, 18, 29, 10.1002/da.10096 · DOI · Paper page
  39. Bogan, 2005, Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study, Journal of Clinical Psychiatry, 66, 73, 10.4088/JCP.v66n0110 · DOI · Paper page
  40. Bogetto, 2000, Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial, Psychiatry Research, 96, 91, 10.1016/S0165-1781(00)00203-1 · DOI
  41. Boyer, 1995, Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis, Psychopharmacology, 10, 45
  42. Cowley, 1997, Determinants of pharmacologic treatment failure in panic disorder, Journal of Clinical Psychiatry, 58, 555, 10.4088/JCP.v58n1208 · DOI · Paper page
  43. Crocq, 2002, Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment, European Psychiatry, 17, 296, 10.1016/S0924-9338(02)00673-9 · DOI
  44. D'Amico, 2003, Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder, Progress in Neuro-psychopharmacology & Biological Psychiatry, 27, 619, 10.1016/S0278-5846(03)00050-2 · DOI
  45. Deeks, 2005, Cochrane Reviewers’ Handbook 4.2.5 [updated May 2005]
  46. Denys, 2002, Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study, Journal of Clinical Psychiatry, 63, 700, 10.4088/JCP.v63n0807 · DOI · Paper page
  47. Denys, 2004, The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence, Journal of Clinical Psychiatry, 65 Suppl 14, 11
  48. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  49. Francobandiera, 2001, Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study, Canadian Journal of Psychiatry, 46, 356, 10.1177/070674370104600408 · DOI · Paper page
  50. Goodman, 1989, The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability, Archives of General Psychiatry, 46, 1006, 10.1001/archpsyc.1989.01810110048007 · DOI · Paper page
  51. Guy, 1976, ECDEU assessment manual for psychopharmacology
  52. Hamilton, 1959, The assessment of anxiety states by rating, British Journal of Medical Psychology, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  53. Hamilton, 1960, A rating scale for depression, Journal of Neurology, Neurosurgery & Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  54. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  55. Hollander, 2002, Refractory Obsessive-Compulsive Disorder: State-of-the-Art treatment, Journal of Clinical Psychiatry, 63 Suppl 6, 20
  56. Jacobsen, 1995, Risperidone in the treatment of affective illness and obsessive-compulsive disorder, Journal of Clinical Psychiatry, 56, 423
  57. Karno, 1988, The epidemiology of obsessive-compulsive disorder in five US communities, Archives of General Psychiatry, 45, 1094, 10.1001/archpsyc.1988.01800360042006 · DOI · Paper page
  58. Kessler, 1994, Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey., Archives of General Psychiatry, 51, 8, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
  59. Kessler, 2005, Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication, Archives of General Psychiatry, 62, 593, 10.1001/archpsyc.62.6.593 · DOI · Paper page
  60. Koran, 2000, Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder, Journal of Clinical Psychiatry, 61, 514, 10.4088/JCP.v61n0709 · DOI · Paper page
  61. Lafleur, 2006, N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder, Psychopharmacology, 184, 254, 10.1007/s00213-005-0246-6 · DOI · Paper page
  62. Law, 2003, Speech and language therapy interventions for children with primary speech and language delay or disorder, The Cochrane Database of Systematic Reviews
  63. Maina, 2003, Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?, International Clinical Psychopharmacology, 18, 23, 10.1097/00004850-200301000-00004 · DOI · Paper page
  64. McDougle, 1995, Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases, Journal of Clinical Psychiatry, 56, 526
  65. Metin, 2003, Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial, Human Psychopharmacology, 18, 463, 10.1002/hup.512 · DOI · Paper page
  66. Misri, 2004, Obsessive-compulsive disorder in the postpartum: open-label trial of quetiapine augmentation, Journal of Clinical Psychopharmacology, 24, 624, 10.1097/01.jcp.0000144892.52858.7d · DOI
  67. Mitte, 2005, A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder., Journal of Clinical Psychopharmacology, 25, 141, 10.1097/01.jcp.0000155821.74832.f9 · DOI · Paper page
  68. Mitte, 2005, A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia, Journal of Affective Disorders, 88, 27, 10.1016/j.jad.2005.05.003 · DOI · Paper page
  69. Murray, 1994, The global burden of disease in 1990: summary results, sensitivity analysis and future directions, Bulletin of the World Health Organisation, 72, 495
  70. Pallanti, 2002, Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial, Journal of Clinical Psychiatry, 63, 796, 10.4088/JCP.v63n0908 · DOI · Paper page
  71. Pfanner, 2000, Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study, International Clinical Psychopharmacology, 15, 297, 10.1097/00004850-200015050-00007 · DOI · Paper page
  72. Power, 1990, Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care, British Journal of General Practice, 40, 289
  73. Ravizza, 1996, Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD), Psychopharmacology Bulletin, 32, 677
  74. Saxena, 1996, Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder, Journal of Clinical Psychiatry, 57, 303
  75. Schulz, 1995, Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA, 273, 408, 10.1001/jama.1995.03520290060030 · DOI
  76. Simon, 2002, Citalopram for social anxiety disorder: an open-label pilot study in refractory and nonrefractory patients, CNS Spectrums, 7, 655, 10.1017/S1092852900022148 · DOI
  77. Stein, 1995, Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder, International Clinical Psychopharmacology, 10, 11, 10.1097/00004850-199503000-00002 · DOI · Paper page
  78. Stein, 2006, Pharmacotherapt for posttraumatic stress disorder., Cochrane Database of Systematic Reviews
  79. Thomsen, 2004, Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: a case-series, Annals of Clinical Psychiatry, 16, 201, 10.1080/10401230490522016 · DOI
  80. Ware, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Medical Care, 30, 473, 10.1097/00005650-199206000-00002 · DOI · Paper page
  81. Weiss, 1999, Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series, Journal of Clinical Psychiatry, 60, 524, 10.4088/JCP.v60n0804 · DOI · Paper page
  82. Bandelow, 2002, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders, World Journal of Biological Psychiatry, 3, 171, 10.3109/15622970209150621 · DOI · Paper page

Cited by

See all 93

Metadata

Authors
Ipser, J. C., Carey, P., Dhansay, Y., Fakier, N., Seedat, S., & Stein, D. J.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2006-10-18
Issue
4
Pages
CD005473-CD005473
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2151539166
Cited by
93
References
37
FWCI
8.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. https://app.cochat.ai/papers/10.1002/14651858.cd005473.pub2
The paper
Ipser, J. C., Carey, P., Dhansay, Y., Fakier, N., Seedat, S., & Stein, D. J. (2006). Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd005473.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.